Quick Answer
Zenas BioPharma, Inc. reported Earnings Per Share Diluted of $8.44 (loss) per share for the year ending 2025.
- Zenas BioPharma, Inc. showed an increase of +29.0% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Zenas BioPharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2023: $1.96 per share | Q1 2024: $17.89 (loss) per share | Q2 2024: $24.23 (loss) per share | Q3 2024: $5.02 (loss) per share | Q1 2025: $0.80 (loss) per share | Q2 2025: $1.25 (loss) per share | Q3 2025: $1.22 (loss) per share.
- Over the full 3 years of available data (2023 to 2025), Zenas BioPharma, Inc.'s Earnings Per Share Diluted has grown by 65.2%.
- Historical annual values: Fiscal year 2025: $8.44 (loss) per share | Fiscal year 2024: $11.89 (loss) per share | Fiscal year 2023: $24.25 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: